Dynavax Technologies Corporation (DVAX)
USD 10.39
(-2.44%)
USD 10.39
(-2.44%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -6.38 Million USD | -102.18% |
| 2022 | 293.15 Million USD | 282.15% |
| 2021 | 76.71 Million USD | 183.59% |
| 2020 | -91.77 Million USD | 39.38% |
| 2019 | -151.39 Million USD | 4.72% |
| 2018 | -158.89 Million USD | -66.99% |
| 2017 | -95.15 Million USD | 15.38% |
| 2016 | -112.44 Million USD | -5.29% |
| 2015 | -106.79 Million USD | -17.72% |
| 2014 | -90.72 Million USD | -35.97% |
| 2013 | -66.72 Million USD | 4.62% |
| 2012 | -69.94 Million USD | -43.94% |
| 2011 | -48.59 Million USD | 15.2% |
| 2010 | -57.3 Million USD | -87.5% |
| 2009 | -30.56 Million USD | -46.74% |
| 2008 | -20.82 Million USD | 65.27% |
| 2007 | -59.97 Million USD | -15.21% |
| 2006 | -52.05 Million USD | -153.23% |
| 2005 | -20.55 Million USD | -28.7% |
| 2004 | -15.97 Million USD | 7.96% |
| 2003 | -17.35 Million USD | 3.8% |
| 2002 | -18.03 Million USD | 2.03% |
| 2001 | -18.41 Million USD | 31.1% |
| 2000 | -26.72 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 11.38 Million USD | 230.56% |
| 2024 Q1 | -8.72 Million USD | -4082.19% |
| 2023 Q2 | 3.43 Million USD | 114.1% |
| 2023 Q1 | -24.33 Million USD | -135.92% |
| 2023 Q4 | 219 Thousand USD | -98.47% |
| 2023 Q3 | 14.29 Million USD | 316.58% |
| 2023 FY | -6.38 Million USD | -102.18% |
| 2022 Q2 | 128.75 Million USD | 293.41% |
| 2022 FY | 293.15 Million USD | 282.15% |
| 2022 Q4 | 67.73 Million USD | 6.15% |
| 2022 Q3 | 63.8 Million USD | -50.44% |
| 2022 Q1 | 32.72 Million USD | -67.2% |
| 2021 Q3 | -28.43 Million USD | -786.71% |
| 2021 Q2 | 4.14 Million USD | 404.26% |
| 2021 Q4 | 99.77 Million USD | 450.96% |
| 2021 Q1 | 821 Thousand USD | 105.31% |
| 2021 FY | 76.71 Million USD | 183.59% |
| 2020 Q3 | 4.4 Million USD | 108.53% |
| 2020 Q2 | -51.57 Million USD | -309.52% |
| 2020 FY | -91.77 Million USD | 39.38% |
| 2020 Q4 | -15.46 Million USD | -451.44% |
| 2020 Q1 | -12.59 Million USD | 65.73% |
| 2019 FY | -151.39 Million USD | 4.72% |
| 2019 Q1 | -39.67 Million USD | 0.74% |
| 2019 Q2 | -42.71 Million USD | -7.67% |
| 2019 Q3 | -33.45 Million USD | 21.67% |
| 2019 Q4 | -36.75 Million USD | -9.85% |
| 2018 Q3 | -40.52 Million USD | -2.75% |
| 2018 FY | -158.89 Million USD | -66.99% |
| 2018 Q1 | -38.95 Million USD | -42.07% |
| 2018 Q2 | -39.44 Million USD | -1.25% |
| 2018 Q4 | -39.96 Million USD | 1.38% |
| 2017 Q2 | -20.31 Million USD | 19.65% |
| 2017 FY | -95.15 Million USD | 15.38% |
| 2017 Q4 | -27.42 Million USD | -23.92% |
| 2017 Q3 | -22.12 Million USD | -8.91% |
| 2017 Q1 | -25.28 Million USD | -16.31% |
| 2016 Q1 | -27.02 Million USD | -0.6% |
| 2016 Q2 | -28.98 Million USD | -7.26% |
| 2016 Q4 | -21.74 Million USD | 37.33% |
| 2016 Q3 | -34.69 Million USD | -19.69% |
| 2016 FY | -112.44 Million USD | -5.29% |
| 2015 Q1 | -26.21 Million USD | -17.64% |
| 2015 Q2 | -23.59 Million USD | 10.02% |
| 2015 Q4 | -26.86 Million USD | 10.83% |
| 2015 Q3 | -30.12 Million USD | -27.69% |
| 2015 FY | -106.79 Million USD | -17.72% |
| 2014 FY | -90.72 Million USD | -35.97% |
| 2014 Q4 | -22.28 Million USD | 25.26% |
| 2014 Q1 | -13.84 Million USD | -6.0% |
| 2014 Q2 | -24.77 Million USD | -79.02% |
| 2014 Q3 | -29.81 Million USD | -20.35% |
| 2013 Q3 | -15.67 Million USD | 8.68% |
| 2013 Q4 | -13.05 Million USD | 16.71% |
| 2013 Q1 | -20.82 Million USD | -1.37% |
| 2013 FY | -66.72 Million USD | 4.62% |
| 2013 Q2 | -17.16 Million USD | 17.58% |
| 2012 Q3 | -17.79 Million USD | -17.74% |
| 2012 Q2 | -15.11 Million USD | 8.45% |
| 2012 Q1 | -16.5 Million USD | -286.81% |
| 2012 FY | -69.94 Million USD | -43.94% |
| 2012 Q4 | -20.54 Million USD | -15.47% |
| 2011 FY | -48.59 Million USD | 15.2% |
| 2011 Q4 | -4.26 Million USD | 71.98% |
| 2011 Q1 | -18.46 Million USD | -22.11% |
| 2011 Q2 | -10.63 Million USD | 42.41% |
| 2011 Q3 | -15.22 Million USD | -43.2% |
| 2010 Q3 | -4.99 Million USD | 82.15% |
| 2010 Q1 | -9.18 Million USD | 69.66% |
| 2010 Q2 | -28 Million USD | -204.92% |
| 2010 FY | -57.3 Million USD | -87.5% |
| 2010 Q4 | -15.12 Million USD | -202.56% |
| 2009 Q4 | -30.27 Million USD | -218.43% |
| 2009 FY | -30.56 Million USD | -46.74% |
| 2009 Q3 | -9.5 Million USD | -331.29% |
| 2009 Q2 | 4.11 Million USD | -19.43% |
| 2009 Q1 | 5.1 Million USD | 64.6% |
| 2008 Q2 | -6.07 Million USD | 51.09% |
| 2008 Q1 | -12.42 Million USD | -2.92% |
| 2008 FY | -20.82 Million USD | 65.27% |
| 2008 Q4 | 3.09 Million USD | 157.18% |
| 2008 Q3 | -5.42 Million USD | 10.84% |
| 2007 Q4 | -12.07 Million USD | 29.38% |
| 2007 Q3 | -17.1 Million USD | 3.41% |
| 2007 Q2 | -17.7 Million USD | -35.25% |
| 2007 Q1 | -13.09 Million USD | 20.45% |
| 2007 FY | -59.97 Million USD | -15.21% |
| 2006 Q1 | -8.17 Million USD | 6.73% |
| 2006 Q2 | -15.27 Million USD | -86.89% |
| 2006 FY | -52.05 Million USD | -153.23% |
| 2006 Q3 | -12.15 Million USD | 20.43% |
| 2006 Q4 | -16.45 Million USD | -35.41% |
| 2005 Q3 | -8.28 Million USD | 3.44% |
| 2005 Q4 | -8.76 Million USD | -5.77% |
| 2005 FY | -20.55 Million USD | -28.7% |
| 2005 Q1 | 5.07 Million USD | 198.2% |
| 2005 Q2 | -8.57 Million USD | -269.21% |
| 2004 Q3 | -4.03 Million USD | -38.64% |
| 2004 Q4 | -5.16 Million USD | -28.02% |
| 2004 Q1 | -3.86 Million USD | 14.85% |
| 2004 FY | -15.97 Million USD | 7.96% |
| 2004 Q2 | -2.9 Million USD | 24.75% |
| 2003 FY | -17.35 Million USD | 3.8% |
| 2003 Q2 | -3.95 Million USD | 16.17% |
| 2003 Q3 | -4.13 Million USD | -4.65% |
| 2003 Q1 | -4.71 Million USD | 0.0% |
| 2003 Q4 | -4.54 Million USD | -9.69% |
| 2002 FY | -18.03 Million USD | 2.03% |
| 2001 FY | -18.41 Million USD | 31.1% |
| 2000 FY | -26.72 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 113.268% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -106.194% |
| Embecta Corp. | 70.4 Million USD | 109.075% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 115.228% |
| PainReform Ltd. | -9.34 Million USD | 31.625% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -41.787% |
| SCYNEXIS, Inc. | 67.04 Million USD | 109.53% |
| Journey Medical Corporation | -3.85 Million USD | -65.819% |
| Safety Shot Inc | -15.08 Million USD | 57.641% |
| Alpha Teknova, Inc. | -36.78 Million USD | 82.629% |
| Bright Green Corporation | -13.12 Million USD | 51.332% |
| Procaps Group, S.A. | 42.54 Million USD | 115.019% |
| Alvotech | -551.73 Million USD | 98.842% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 134.022% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 18.818% |
| Cosmos Health Inc. | -18.54 Million USD | 65.544% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 96.947% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 95.426% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -41.787% |
| Theratechnologies Inc. | -23.95 Million USD | 73.331% |
| Harrow Health, Inc. | -24.41 Million USD | 73.827% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -32.141% |
| Biofrontera Inc. | -20.13 Million USD | 68.263% |
| DURECT Corporation | -27.62 Million USD | 76.872% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 585.486% |
| Cronos Group Inc. | -73.96 Million USD | 91.362% |
| OptiNose, Inc. | -35.48 Million USD | 81.994% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 99.363% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 84.86% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 126.714% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 229.201% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 4142.826% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -1.747% |
| Radius Health, Inc. | -25.79 Million USD | 75.228% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -3.666% |
| ProPhase Labs, Inc. | -16.78 Million USD | 61.929% |
| Phibro Animal Health Corporation | 2.41 Million USD | 364.445% |
| Procaps Group S.A. | 42.54 Million USD | 115.019% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 37.838% |
| Viatris Inc. | 54.7 Million USD | 111.68% |
| Rockwell Medical, Inc. | -8.43 Million USD | 24.292% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 59.676% |
| SIGA Technologies, Inc. | 68.06 Million USD | 109.386% |
| Tilray Brands, Inc. | -244.98 Million USD | 97.392% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 153.184% |
| Shineco, Inc. | -22.44 Million USD | 71.54% |
| PetIQ, Inc. | 2.13 Million USD | 399.812% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -48.518% |
| Incannex Healthcare Limited | -18.45 Million USD | 65.388% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 102.559% |
| Alimera Sciences, Inc. | -20.13 Million USD | 68.264% |
| Silver Spike Investment Corp. | 7.34 Million USD | 187.042% |
| Assertio Holdings, Inc. | -331.94 Million USD | 98.075% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 3.09% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 21.734% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 64.305% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 68.146% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 96.014% |
| Hempacco Co., Inc. | -13.12 Million USD | 51.326% |
| Talphera, Inc. | -18.39 Million USD | 65.272% |
| Alvotech | -551.73 Million USD | 98.842% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 117.925% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 101.956% |
| Currenc Group, Inc. | -15.3 Million USD | 58.26% |
| Kamada Ltd. | 8.28 Million USD | 177.125% |
| Indivior PLC | 2 Million USD | 419.45% |
| Evoke Pharma, Inc. | -7.79 Million USD | 18.009% |
| Flora Growth Corp. | -57.03 Million USD | 88.798% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 68.146% |
| Evolus, Inc. | -61.68 Million USD | 89.643% |
| HUTCHMED (China) Limited | 100.78 Million USD | 106.34% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 104.645% |
| Akanda Corp. | -32.27 Million USD | 80.205% |